Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation
Abstract
Triple-negative breast cancers (TNBC) have a relatively poor prognosis and responses to targeted therapies. Between 25 and 39% of TNBCs are claudin-low, a poorly differentiated subtype enriched for mesenchymal, stem cell and mitogen-activated signaling pathways. We investigated the role of the cell-surface co-receptor NRP1 in the biology of claudin-low TNBC.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 25, 2022
- Source ID
- 10.1186/s13058-022-01501-7
Entities
People
- Anja Rockstroh
- Brett G. Hollier
- Colleen Nelson
- Erik W. Thompson
- Kamil A. Sokolowski
- Layla-rose Lynam
- Marianna Volpert
- Melanie Lehman
- Philip A. Gregory
- Yu Hin Tang
Organizations
- United States Department of Defense